Charles River Labs stock trades near TD Cowen target as Amundi trims position
Published on 09/10/2026 at 12:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Charles River Laboratories International Inc. stock (ISIN US1591881009) closed at 283.98 USD on the New York Stock Exchange on September 8, 2026, leaving the shares only a few dollars above the 281 USD average analyst price target and signaling a limited near term upside at that level.
Analyst targets frame the valuation
According to an overview cited by Ad-hoc-news on September 9, 2026, the average analyst price target for Charles River Labs stands at 281 USD, with a lower bound of 145 USD and an upper bound of 318 USD, positioning the September 8, 2026 closing price of 283.98 USD slightly above the consensus midpoint but still below the most optimistic expectations.
The same report notes that TD Cowen raised its price target for Charles River Labs from 235 USD to 300 USD on August 10, 2026 while keeping a Buy rating, meaning the new target sits about 27.7 percent above the previous level and roughly 5.7 percent above the 283.98 USD closing price recorded on September 8, 2026, which underscores that the broker still sees room for further gains despite the recent advance.Ad-hoc-news
Institutional flows and rating backdrop
As MarketBeat reported on September 10, 2026, asset manager Amundi disclosed the sale of 360,913 shares of Charles River Laboratories International Inc., a move that highlights active portfolio adjustments by a major institutional holder at a time when the stock is trading close to key analyst reference levels.
Based on data summarized by MarketBeat, Charles River Labs currently carries an average rating of Moderate Buy and an average price target of 259.44 USD across the covered analysts, a figure that sits below the 283.98 USD closing price from September 8, 2026 and therefore suggests that, relative to this particular consensus, the stock is trading above the typical target range used by many houses.
The coexistence of the 259.44 USD average target reported by MarketBeat and the 281 USD analyst midpoint cited by Ad-hoc-news illustrates that different data sets and coverage universes yield somewhat different views of fair value, but both imply that Charles River Labs stock has recently moved ahead of at least part of the sell side consensus, which can limit further upside unless upcoming earnings deliver a clear positive surprise.
Earnings expectations and risk factors
According to the analyst overview referenced by Ad-hoc-news on September 9, 2026, earnings per share for the quarter ending September 2026 are estimated at 3.07 USD, and this forecast serves as an important benchmark for investors when judging whether the current share price around 283.98 USD still leaves attractive upside relative to TD Cowen's 300 USD target or whether expectations are already fully priced in.
The same coverage emphasizes that Charles River Labs operates as a provider of life science tools and services with a business model heavily exposed to pharmaceutical and biotechnology research budgets, meaning that any slowdown in research and development spending or increased scrutiny of healthcare costs could weigh on demand for preclinical and laboratory services and act as a counter factor to the bullish analyst targets.Ad-hoc-news
Stock level and market context
As of the latest completed trading day, September 8, 2026, Charles River Labs stock closed at 283.98 USD on the NYSE in its US dollar home market, which investors can use as the current reference level when comparing the shares to the 281 USD analyst average and the 300 USD TD Cowen target cited in recent coverage.
Charles River Labs stock facts
- Company: Charles River Laboratories International Inc.
- ISIN: US1591881009
- Ticker: CRL
- Trading venue: NYSE
- Price (as of September 8, 2026, 14:01): 283.98 USD
- Sector / Industry: Healthcare - Life Sciences Tools and Services
- Index membership: S&P 500
